Recombinant Human FGF21 Protein, C-HSA-His

Recombinant Human FGF21 Protein, also known as Fibroblast Growth Factor 21, is a protein that plays a crucial role in regulating metabolism and energy balance in the human body. It is produced through genetic engineering techniques, making it a valuable tool in the field of biotechnology and medical research.

Structure of Recombinant Human FGF21 Protein

The structure of Recombinant Human FGF21 Protein is composed of 209 amino acids, with a molecular weight of approximately 23 kDa. It belongs to the FGF family of proteins, which are known for their diverse functions in cell growth, development, and metabolism. FGF21 is primarily expressed in the liver, but it can also be found in other tissues such as adipose tissue, pancreas, and skeletal muscle.

The protein is made up of three distinct domains: an N-terminal signal peptide, a central β-trefoil domain, and a C-terminal tail. The signal peptide is responsible for targeting the protein to the endoplasmic reticulum, where it undergoes post-translational modifications such as glycosylation. The β-trefoil domain is the functional region of FGF21, responsible for binding to its receptor and initiating downstream signaling pathways. The C-terminal tail is involved in stabilizing the protein and protecting it from degradation.

Activity of Recombinant Human FGF21 Protein

Recombinant Human FGF21 Protein has been extensively studied for its role in regulating energy metabolism. It acts as an endocrine hormone, meaning it is secreted by one tissue and acts on another tissue. FGF21 exerts its effects by binding to a specific receptor called FGFR1c, which is expressed in various tissues, including adipose tissue, liver, and muscle.

One of the main functions of FGF21 is to promote the breakdown of stored fat (lipolysis) and the utilization of fatty acids for energy production. It also enhances insulin sensitivity, which helps regulate blood glucose levels. Additionally, FGF21 has been shown to have anti-inflammatory effects and can protect against obesity-induced insulin resistance and fatty liver disease.

Application of Recombinant Human FGF21 Protein

Due to its potent metabolic effects, Recombinant Human FGF21 Protein has been investigated for various therapeutic applications. It has shown promising results in preclinical studies for the treatment of obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).

In a clinical trial, FGF21 was found to significantly reduce body weight and improve insulin sensitivity in obese individuals with type 2 diabetes. It has also been shown to decrease liver fat content and improve liver function in patients with NAFLD. These findings suggest that FGF21 could be a potential treatment for metabolic disorders associated with obesity.

Furthermore, Recombinant Human FGF21 Protein has been studied for its potential in treating other conditions such as cardiovascular disease and neurodegenerative disorders. Its ability to improve lipid metabolism and promote glucose uptake in the brain makes it a promising candidate for these indications.

Conclusion

In summary, Recombinant Human FGF21 Protein is a crucial protein involved in regulating metabolism and energy balance. Its unique structure and activity make it a valuable tool in scientific research, particularly in the field of metabolic disorders. With ongoing studies and clinical trials, FGF21 could potentially become a novel therapeutic agent for various diseases, providing hope for improved treatments and better health outcomes.

ProteoGenix catalogue number ARO-P10353. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 43.61 kDa; Fragment: His29-Ser209 & Leu404-Ala601 (HSA); Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet